Supervised risk predictor of breast cancer based on intrinsic subtypes.

UNLABELLED PURPOSE To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression-based "intrinsic" subtypes luminal A, luminal B, HER2-enriched, and basal-like. METHODS A 50-gene subtype predictor was developed using microarray and quantitative reverse transcriptase polymerase chain reaction data from 189 prototype samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen. RESULTS The intrinsic subtypes as discrete entities showed prognostic significance (P = 2.26E-12) and remained significant in multivariable analyses that incorporated standard parameters (estrogen receptor status, histologic grade, tumor size, and node status). A prognostic model for node-negative breast cancer was built using intrinsic subtype and clinical information. The C-index estimate for the combined model (subtype and tumor size) was a significant improvement on either the clinicopathologic model or subtype model alone. The intrinsic subtype model predicted neoadjuvant chemotherapy efficacy with a negative predictive value for pCR of 97%. CONCLUSION Diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer. The prognostic properties of the continuous risk score will be of value for the management of node-negative breast cancers. The subtypes and risk score can also be used to assess the likelihood of efficacy from neoadjuvant chemotherapy.

[1]  M. C. Jones,et al.  A reliable data-based bandwidth selection method for kernel density estimation , 1991 .

[2]  J. Marron,et al.  SiZer for Exploration of Structures in Curves , 1999 .

[3]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[5]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[7]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Dudoit,et al.  A prediction-based resampling method for estimating the number of clusters in a dataset , 2002, Genome Biology.

[9]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[10]  Robert Tibshirani,et al.  Statistical methods for identifying differentially expressed genes in DNA microarrays. , 2003, Methods in molecular biology.

[11]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[14]  Puay Hoon Tan,et al.  Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations , 2004, Clinical Cancer Research.

[15]  Alan R. Dabney.  Classification of microarrays to nearest centroids , 2005, Bioinform..

[16]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Rosen,et al.  Stem/Progenitor Cells in Mouse Mammary Gland Development and Breast Cancer , 2005, Journal of Mammary Gland Biology and Neoplasia.

[18]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[19]  Roman Rouzier,et al.  Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Soonmyung Paik,et al.  Gene expression profiling of breast cancer: a new tumor marker. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Zhiyuan Hu,et al.  Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay , 2006, Breast Cancer Research.

[22]  P. Dam,et al.  Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling , 2006, Breast Cancer Research and Treatment.

[23]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[25]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[27]  Yudi Pawitan,et al.  Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients , 2006, Breast Cancer Research.

[28]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[29]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[30]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[31]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[32]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[33]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[34]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[36]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[37]  D. Hayes.  Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer , 2007 .

[38]  E. Winer,et al.  Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.

[39]  A. Howell,et al.  Origins of breast cancer subtypes and therapeutic implications , 2007, Nature Clinical Practice Oncology.

[40]  T. Naab,et al.  Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome , 2007, Annals of Surgical Oncology.

[41]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Therese Sørlie,et al.  Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer , 2007, Molecular oncology.

[43]  E. Liu,et al.  Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine , 2007, Breast Cancer Research.

[44]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[45]  A. Børresen-Dale,et al.  Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes , 2007, Breast Cancer Research.

[46]  Therese Sørlie,et al.  Molecular classification of breast tumors: toward improved diagnostics and treatments. , 2007, Methods in molecular biology.

[47]  Charles M Perou,et al.  Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. , 2007, Clinical chemistry.

[48]  A. Nobel,et al.  Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data , 2008 .

[49]  Daniel Birnbaum,et al.  Reasons for breast cancer heterogeneity , 2008, Journal of biology.

[50]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[51]  C. Desmedt,et al.  Gene expression predictors in breast cancer: current status, limitations and perspectives. , 2008, European journal of cancer.

[52]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.